Search Results

You are looking at 1 - 10 of 15 items for :

  • "remdesivir" x
  • Refine by Access: All Content x
Clear All
Scientia et Securitas
Author: György Miklós Keserű

. 6 Jorgensen, S., Kebriaei, R., & Dresser, L. D. (2020) Remdesivir: Review of Pharmacology, Pre-clinical Data, and Emerging Clinical Experience for COVID-19. Pharmacotherapy, Vol. 40. No. 7. pp

Open access
Orvosi Hetilap
Authors: Ádám Remport, Zsuzsanna Gerlei, Orsolya Cseprekál, László Wagner, Katalin Földes, Adrienn Marton, Attila Patonai, Szilárd Török, Anita Haboub-Sandil, Marina Varga, Attila Doros, Anikó Smudla, János Fazakas, and László Kóbori

–2303. 44 Grein J, Ohmagari N, Shin D, et al. Compassionate use of remdesivir for patients with severe Covid-19. N Engl J Med. 2020; 382: 2327–2336. 45

Open access
Orvosi Hetilap
Authors: Ákos Fábián, István László, Marianna Juhász, Mariann Berhés, Tamás Végh, György Koszta, Csilla Molnár, and Béla Fülesdi

://www.cdc.gov/coronavirus/2019-ncov/hcp/therapeutic-options.html . 2 Agostini ML, Andres EL, Sims AC, et al. Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and

Open access

Gyorsreagálás a pandémiára, ellátásbiztonság

Rapid response to pandemia, supply security

Scientia et Securitas
Author: István Greiner

Összefoglaló. A tavalyi évben kitört COVID–19 pandémia jelentős kihívások elé állította a világot. Nem pusztán a kormányok és az egészségügyi rendszerek szembesültek új, békeidőben eddig még nem gyakorolt feladatokkal, de a tudományos világnak is át kellett tekinteni mind a régi, mind a legmodernebb eszközöket ahhoz, hogy a vírus terjedésének, a betegek szenvedéseinek, a tömeges halálozásoknak végre véget lehessen vetni. Habár a járványnak még messze nincsen vége, és egyre újabb és újabb mutánsok ütik fel a fejüket a világ legkülönbözőbb részein, mégis azokat a tanulságokat, melyek már összegyűltek a gyógyszeripar területén, érdemes összefoglalni. Talán még ennél is fontosabb azonban, hogy azokat a hiányokat, amelyeket még be kell pótolni, szintén megemlítsük, hogy ezzel is segítsük az újabb hullámok vagy járványok leküzdését.

Summary. During the last 12 months the most serious issue was the SARS-CoV-2 virus generated pandemia around the world. There is no country which could be more or less intact and a huge amount of resources was sacrificed to rescue people from the fatal outcome of this disease. When it started a year ago or more, there were doubts about its future but later it was realised that this is an epidemic occurring worldwide, crossing international boundaries, and affecting a large number of people. According to the WHO, today the number of confirmed cases is about 157.8 million, confirmed deaths are 3.3 million and 1.2 billion vaccine doses have been administered. These numbers clearly show how important it is to elaborate the reaction of the pharma industry and investigate how to ensure safe drug supply for patients in every country. The topics discussed below are the basic and unique features of the SARS-CoV-2 virus, the pandemia generated by it, and the role of the Hungarian pharma industry, especially Gedeon Richter plc, during this critical period. On one hand the author explains how the spread of virus can be decreased in general and at a production facility like Richter, and on the other hand R&D activity of the Company aiming to cure patients suffering from COVID-19 infection. Consortia including universities, academia and industrial entities made a substantial impact on handling this terrible epidemic. Gedeon Richter plc, the biggest and only independent Hungarian pharma company, in keeping with its roots started small molecule R&D to make favipiravir and remdesivir available to clinics. The latter production is a very difficult one but using its background in chemistry Richter was able to manage all R&D and industrial scale up activities in six months. Moreover, it has filed two patent applications about its new, more feasible and economical process steps justifying its innovative attitude. As a final conclusion it is stated that for the safe supply of necessary medication one critical step is missing from the capabilities of the Hungarian pharma industry, the vaccine R&D and production.

Open access

] 15 Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the Treatment of Covid-19 – Preliminary Report. N Engl J Med. 2020 May 22. 10.1056/NEJMoa2007764 . [Published online ahead of print

Full access
Orvosi Hetilap
Authors: Botond Lakatos, László Gopcsa, Enikő Gondos, Alexandra Riczu, Zsuzsa Várnai, Éva Nagy, Eszter Molnár, Gabriella Bekő, Ilona Bobek, Péter Reményi, János Szlávik, János Sinkó, and István Vályi-Nagy

: April 28, 2020]. 35 Grein J, Ohmagari N, Shin D, et al. Compassionate use of remdesivir for patients with severe Covid-19. N Engl J Med. 2020 Apr 10

Open access

Antivirális és gyulladásellenes kezelési lehetőségek COVID–19-ben

Antiviral and anti-inflammatory therapies in COVID-19

Orvosi Hetilap
Authors: Zoltán Szekanecz, Krisztina Bogos, Tamás Constantin, Béla Fülesdi, Veronika Müller, Éva Rákóczi, István Várkonyi, and István Vályi-Nagy

-CoV-2. Antimicrob Agents Chemother. 2020; 64: e01101–20. 14 Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the treatment of Covid-19 – final report. N Engl J Med

Open access

circumstances or the symptoms. Antiviral drugs The antiviral prodrugs favipiravir, geldesivir, ribavirin, and remdesivir are nucleoside analogues. Remdesivir was tested against Ebola and Marburg virus infections without success, but it is a promising therapy for

Open access

A súlyos akut légzőszervi szindrómát okozó koronavírus-2 (SARS-CoV-2) orvosilag releváns aspektusai állatokban

Medically relevant aspects of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in animals

Orvosi Hetilap
Authors: Anna Valkó and Melinda Medgyaszai

Immunology (EAACI). Allergy 2020; 75: 2445–2476. 47 Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the treatment of COVID-19 – final report. N Engl

Open access

Az új típusú koronavírus okozta megbetegedés (COVID–19): összefoglaló hematológusoknak II. – a diagnosztika, terápia és prevenció lehetőségei

The novel coronavirus disease (COVID-19): a review for specialists in hematology II – aspects of diagnosis, therapy and prevention

Hematológia–Transzfuziológia
Authors: Bálint Gergely Szabó, Ilona Bobek, Marienn Réti, László Gopcsa, Dóra Mathiász, Botond Lakatos, Gabriella Bekő, Mónika Pető, János Sinkó, Gábor Mikala, Zoltán Kis, János Szlávik, Péter Reményi, and István Vályi-Nagy

(COVID-19). Ann Intern Med. 2020. [epub, accessed: May 25, 2020] 42 Wang Y, Zhang D, Du G, et al. Remdesivir in adults with severe COVID-19: a

Open access